Literature DB >> 19564562

Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries.

Gregory J Wilson1, Gaku Nakazawa, Robert S Schwartz, Barbara Huibregtse, Bradley Poff, Thomas J Herbst, Donald S Baim, Renu Virmani.   

Abstract

BACKGROUND: Although both sirolimus (CYPHER) and paclitaxel (TAXUS) drug-eluting stents have demonstrated efficacy and safety in clinical trials, human autopsy data have raised concerns about long-term healing and the potential for local inflammatory reactions. METHODS AND
RESULTS: Overlapping stents (CYPHER drug-eluting stents, Bx SONIC bare metal stents, TAXUS drug-eluting stents, and Liberté bare metal stents) were implanted in noninjured coronary arteries of 58 domestic swine. Histopathological evaluation of proximal, overlapped, and distal stented segments was determined with emphasis on inflammation at 30, 90, and 180 days. Circumferential granulomatous inflammation in all stented segments was defined as inflammation consisting of macrophages, multinucleated giant cells, lymphocytes, and granulocytes, including many eosinophils, adjacent to almost all struts. Circumferential granulomatous inflammation was more prevalent in CYPHER (9 of 23, 39%) compared with TAXUS (1 of 21, 5%; P=0.01) and control bare metal stents (0 of 44) in the combined 90- and 180-day cohorts. Only CYPHER specimens showed marked adventitial inflammation (P=0.0025) and fibrosis (P=0.0055) accompanied by extensive remodeling. Fibrin deposition within neointima and medial smooth muscle cell death were greater (both P<0.001) in TAXUS than CYPHER at 30 days, with more fibrin in TAXUS than CYPHER through 90 days (P<0.05).
CONCLUSIONS: Although these data cannot be directly extrapolated to humans, the high prevalence in this porcine model of diffuse granulomatous inflammation seen with CYPHER stents, persisting at 180 days and associated with extensive remodeling of the artery, and persistent para-strut fibrin deposition with TAXUS stents emphasize the need for further investigation of biocompatibility with these and other novel combination drug/polymer drug-eluting stents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19564562     DOI: 10.1161/CIRCULATIONAHA.107.730010

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  45 in total

1.  Low-dose sirolimus-eluting hydroxyapatite coating on stents does not increase platelet activation and adhesion ex vivo.

Authors:  Carlos L Alviar; Armando Tellez; Michael Wang; Pamela Potts; Doug Smith; Manus Tsui; Wladyslaw Budzynski; Albert E Raizner; Neal S Kleiman; Eli I Lev; Juan F Granada; Greg L Kaluza
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

2.  Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.

Authors:  Salvatore Brugaletta; Hector M Garcia-Garcia; Scot Garg; Josep Gomez-Lara; Roberto Diletti; Yoshinobu Onuma; Robert Jan van Geuns; Dougal McClean; Dariusz Dudek; Leif Thuesen; Bernard Chevalier; Stephan Windecker; Robert Whitbourn; Cecile Dorange; Karine Miquel-Hebert; Krishnankutty Sudhir; John A Ormiston; Patrick W Serruys
Journal:  Int J Cardiovasc Imaging       Date:  2010-10-13       Impact factor: 2.357

3.  Sustained Efficacy and Arterial Drug Retention by a Fast Drug Eluting Cross-Linked Fatty Acid Coronary Stent Coating.

Authors:  Natalie Artzi; Abraham R Tzafriri; Keith M Faucher; Geoffrey Moodie; Theresa Albergo; Suzanne Conroy; Scott Corbeil; Paul Martakos; Renu Virmani; Elazer R Edelman
Journal:  Ann Biomed Eng       Date:  2015-08-28       Impact factor: 3.934

Review 4.  Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis.

Authors:  Teruo Inoue; Kevin Croce; Toshifumi Morooka; Masashi Sakuma; Koichi Node; Daniel I Simon
Journal:  JACC Cardiovasc Interv       Date:  2011-10       Impact factor: 11.195

5.  Free radical functionalization of surfaces to prevent adverse responses to biomedical devices.

Authors:  Marcela M M Bilek; Daniel V Bax; Alexey Kondyurin; Yongbai Yin; Neil J Nosworthy; Keith Fisher; Anna Waterhouse; Anthony S Weiss; Cristobal G dos Remedios; David R McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-15       Impact factor: 11.205

Review 6.  Drug-Eluting Balloons and Drug-Eluting Stents in the Treatment of Peripheral Vascular Disease.

Authors:  Jonathan Lindquist; Kristofer Schramm
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

7.  Optical coherence tomography images of bell-shaped appearance in late sirolimus-eluting stent restenosis with extension of previous incomplete stent apposition.

Authors:  Tomokazu Iguchi; Takao Hasegawa; Satoshi Nishimura; Shinji Nakata; Toru Kataoka; Shoichi Ehara; Kenei Shimada; Akihisa Hanatani; Takashi Muro; Minoru Yoshiyama
Journal:  J Cardiol Cases       Date:  2011-08-27

8.  Preclinical comparative assessment of a dedicated pediatric poly-L-lactic-acid-based bioresorbable scaffold with a low-profile bare metal stent.

Authors:  Kamel Shibbani; Luiza De Lima E Silva Bagno; Marie-France Poulin; Thomas Matella; Karim Diab; Clifford Kavinsky; Nagarajan Ramesh; Vinayak Bhat; Ziyad M Hijazi; Damien Kenny
Journal:  Catheter Cardiovasc Interv       Date:  2020-04-15       Impact factor: 2.692

9.  Novel small leucine-rich repeat protein podocan is a negative regulator of migration and proliferation of smooth muscle cells, modulates neointima formation, and is expressed in human atheroma.

Authors:  Randolph Hutter; Li Huang; Walter S Speidl; Chiara Giannarelli; Paul Trubin; Gerhard Bauriedel; Mary E Klotman; Valentin Fuster; Juan J Badimon; Paul E Klotman
Journal:  Circulation       Date:  2013-09-16       Impact factor: 29.690

10.  Temporal course of neointimal hyperplasia following drug-eluting stent implantation: a serial follow-up optical coherence tomography analysis.

Authors:  Seung-Yul Lee; Myeong-Ki Hong; Gary S Mintz; Dong-Ho Shin; Jung-Sun Kim; Byeong-Keuk Kim; Young-Guk Ko; Donghoon Choi; Yangsoo Jang
Journal:  Int J Cardiovasc Imaging       Date:  2014-05-08       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.